## Application No. 09/701,437

Cl

9. (Three Times Amended) A method as claimed in claim 1, in which the compound is designed or selected to interact with the β-sheet of the L1 domain causing an alteration in the position of the L1 domain relative to the position of the S1 domain or the L2 domain.

 $\mathcal{C}^{\mathcal{L}}$ 

- 12 (Three Times Amended) A method as claimed in claim 1, in which the compound is designed or selected to interact with the  $\beta$ -sheet of the L2 domain causing an alteration in the position of the L2 domain relative to the position of the S2 domain.
- 13. (Three Times Amended) A method as claimed in claim 1 in which the compound is designed or selected to bind to a lower face containing the second β-sheet of the L1 and/or L2 domains, wherein the structure of the face is characterized by a plurality of solvent-exposed hydrophobic residues.

and.

54. (Amended) A method according to claim 1, wherein the testing in step (C) is carried out *in vitro*.

autolic U

56. (Amended) A method according to claim 1, wherein the testing in step (C) is carried out *in vivo*.